Page last updated: 2024-11-06

3-methylflavone-8-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-methylflavone-8-carboxylic acid: metabolite of flavoxate; RN in Chemline for the Na salt: 58348-97-3 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-methylflavone-8-carboxylic acid : A member of the class of flavones that is flavone substituted at position 3 by a methyl group and at position 8 by a carboxylic acid group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID77016
CHEMBL ID1615
CHEBI ID61237
SCHEMBL ID2480956
MeSH IDM0057848

Synonyms (44)

Synonym
3468-01-7
AC-103
EN300-17190
unii-o8rcm70c48
o8rcm70c48 ,
einecs 222-425-2
ENAMINE_005545 ,
3-methylflavone-8-carboxylic acid
HMS1409M01
CHEMBL1615
chebi:61237 ,
8-carboxy-3-methylflavone
3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylic acid
FT-0657025
3-methyl-4-oxo-2-phenyl-4h-chromene-8-carboxylic acid
STK801454
3-methyl-4-oxo-2-phenylchromene-8-carboxylic acid
AKOS000120623
BBL010098
4h-1-benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-
FT-0616159
3-methyl-2-phenylchromone-8-carboxylic acid
M2371
LMPK12113395
flavoxate hydrochloride impurity a [ep impurity]
8-carboxy-3-methyl-4-oxo-2-phenyl-4h-1-benzopyran
sr-01000041080
SR-01000041080-1
SCHEMBL2480956
3-methylflavone-8-carboxylic acid (mfca)
W-106715
3-methylflavone-8-carboxaldehyde
3-methyl-4-oxo-2-phenyl-4h-chromene-8-carboxylic acid #
mfcd00040998
DTXSID00188231
Z56899057
FT-0671781
VS-02315
Q27130916
BCP10531
AMY37080
3-methyl-4-oxo-2-phenyl-4h-chromene-8-carboxylicacid
flavoxate impurity a
CS-W012276

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Taking the advantage that 3-methylflavone-8-carboxylic acid is also the alkaline degradate, the proposed method was applied to in vitro determination of flavoxate hydrochloride in tablets dosage form via the measurement of its corresponding degradate."( Spectrofluorimetric determination of 3-methylflavone-8-carboxylic acid, the main active metabolite of flavoxate hydrochloride in human urine.
Abdelkawy, M; Hawwam, MA; Mohamed, AO; Zaazaa, HE, 2015
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.1.4.* (phosphoric diester hydrolase) inhibitorAn EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a phosphoric diester hydrolase (EC 3.1.4.*).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
flavonesA member of the class of flavonoid with a 2-aryl-1-benzopyran-4-one (2-arylchromen-4-one) skeleton and its substituted derivatives.
oxo monocarboxylic acidAny monocarboxylic acid having at least one additional oxo functional group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID357254Antifungal activity against Candida albicans ATCC 900282002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID622584Inhibition of NF-kappaB activation expressed in HCT116 cells assessed as inhibition of TNF-alpha-induced transcriptional activation at 10 uM after 12 hrs by luciferase reporter gene assay relative to control2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Relationship between the structures of flavonoids and their NF-κB-dependent transcriptional activities.
AID357253Inhibition of Saccharomyces cerevisiae fatty acid synthase2002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
AID357255Antifungal activity against Cryptococcus neoformans ATCC 901132002Journal of natural products, Dec, Volume: 65, Issue:12
Fatty acid synthase inhibitors from plants: isolation, structure elucidation, and SAR studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (15.38)18.7374
1990's2 (15.38)18.2507
2000's4 (30.77)29.6817
2010's5 (38.46)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.59 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]